Just two weeks left to enter the 2025 Diabetes Nursing Awards
With just two weeks remaining until entries close for the 2025 Diabetes Nursing Awards, registered healthcare professionals working in diabetes care are encouraged to submit their applications before the deadline on Friday, March 21.
Organised by Orange Juice Communications, a leader in healthcare communications, events and education, the awards celebrate the outstanding contributions of diabetes nurses across the UK.
This prestigious event recognises excellence, dedication, and innovation within the field, providing a platform for nurses to share best practices and inspire advancements in diabetes care.
Emily Mayhew, Campaigns and Events Manager, Orange Juice Communications, said: “Nurses play a vital role in diabetes care, offering expertise and compassionate support to individuals and communities.
“The Diabetes Nursing Awards celebrate their incredible work and provide well-deserved recognition for their dedication. With just two weeks to go, we encourage all eligible nurses to seize this opportunity to showcase their achievements.”
Award categories for 2025 include:
Community DSN of the Year
Inpatient DSN of the Year
Innovation Award
Paediatric Nurse of the Year
Diabetes Educator of the Year
Excellence Award
Research Project of the Year
Rising Star Award
To support entrants in preparing strong submissions, a free webinar offering practical tips and guidance was recently held. The recording is now available here, providing valuable insights for those looking to enhance their entries.
Entries are free of charge and open until midnight on March 21, 2025. The shortlist of finalists will be announced on Tuesday, April 8, 2025, with the winners revealed during a celebratory dinner and ceremony hosted by Dr Sarah Jarvis MBE at the Radisson Blu Hotel, Bloomsbury, London, on Friday, June 6, 2025.
For more information about the Diabetes Nursing Awards and to enter visit: www.diabetesnursingawards.co.uk
The Diabetes Nursing Awards 2025 has been funded by A. Menarini Farmaceutica Internazionale SRL and embecta which have had no input into any arrangements or content.